| 摘要 |
An erythropoietin (EPO) composition (I) consists mainly or completely of glycosylised EPO molecules and comprises at least 75% tetra-antenna structures with respect to the total N-bound carbohydrate chains present. Independent claims are also included for the following: (1) (I) comprising on average 3.7 units N-acetyl-lactosamine with respect to an N-bound carbohydrate chain to an EPO molecule, and 11.1 units of N-acetyl-lactosamine with respect to the total N-glycosylation of an EPO molecules; (2) (I) where the average product of the multiplication of N-acetyl-lactosamine/carbohydrate chain/EPO molecule times sialinic acid content is 43.3 or 130, when multiplying with N-acetyl-lactosamine/total N-glycosylation with sialinic acid; (3) a pharmaceutical composition comprising (I) and diluents, carriers and other additives; (4) a preparation of (I) comprising: (a) selecting a production cell which can produce carbohydrate chains with a high content of tetra-antenna structures and/or N-acetyl-lactosamine content; (b) selecting of culture conditions which promotes the cells of (a); and (c) separating the undesired products from the EPO molecules chains with a high content of tetra-antenna structures and/or N-acetyl-lactosamine content; and (5) a method for increasing the specific activity of (I), comprising concentrating (I) so that (I) has: (a) a high content of tetra-antenna carbohydrate structures; (b) a large number of N-acetyl-lactosamine units; (c) a high product of N-acetyl-lactosamine units and sialinic acid; (d) a high content of N-acetyl-lactosamine repeats; and/or (e) a high product of N-acetyl-lactosamine repeats and tetra-antenna carbohydrate structures. |
